Literature DB >> 7962468

Hepatic metabolism and distribution of mifepristone and its metabolites in rats.

O Heikinheimo1, U Pesonen, R Huupponen, M Koulu, P Lähteenmäki.   

Abstract

The hepatic metabolism of mifepristone was studied in female Wistar rats following oral administration of 10 mg/kg. The extraction of mifepristone by the rat liver was effective, eliminating 80% of the mifepristone. During the absorption phase, the portal serum concentrations of mifepristone were over 10-fold higher than those measured in systemic serum. The serum concentrations of the monodemethylated, didemethylated and hydroxylated metabolites of mifepristone were lower in systemic serum, indicating that the metabolites were also effectively excreted by the rat liver. The distribution of mifepristone and its demethylated metabolites between serum, brain, muscle and adipose tissue was studied in lean and obese Zucker rats following repeated oral administration of 10 mg/kg. The individual serum concentrations of mifepristone varied considerably, from 24-482 ng/ml; the mean (+/- SE) serum concentrations for lean and obese rats were 167 (+/- 86) and 211 (+/- 62) ng/ml respectively. Mifepristone could be measured in brain in each animal, its concentrations being 28% of those measured in serum. Muscle tissue and serum contained approximately similar concentrations of mifepristone. Adipose tissue effectively concentrated mifepristone, and its concentrations were 40-fold higher in fat than in serum. The difference in the concentrations of mifepristone between the lean and obese animals was statistically significant only in brain tissue (P < 0.05). The serum concentrations and brain, muscle and adipose tissue concentrations of mifepristone were significantly correlated (P < 0.05). The distribution of the demethylated metabolites was roughly similar to that of mifepristone. However, their concentrations were significantly higher (P < 0.02) in the obese animals in each tissue type investigated.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7962468     DOI: 10.1093/humrep/9.suppl_1.40

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  13 in total

1.  Plasma IL-12 levels are suppressed in vivo by stress and surgery through endogenous release of glucocorticoids and prostaglandins but not catecholamines or opioids.

Authors:  Lee Shaashua; Ella Rosenne; Elad Neeman; Liat Sorski; Luba Sominsky; Pini Matzner; Gayle G Page; Shamgar Ben-Eliyahu
Journal:  Psychoneuroendocrinology       Date:  2014-01-07       Impact factor: 4.905

2.  CRF-1 antagonist and CRF-2 agonist decrease binge-like ethanol drinking in C57BL/6J mice independent of the HPA axis.

Authors:  Emily G Lowery; Marina Spanos; Montserrat Navarro; Angela M Lyons; Clyde W Hodge; Todd E Thiele
Journal:  Neuropsychopharmacology       Date:  2010-02-03       Impact factor: 7.853

3.  Glucocorticoid mechanisms may contribute to ECT-induced retrograde amnesia.

Authors:  Nandakumar Nagaraja; Chittaranjan Andrade; Suresh Sudha; Nagendra Madan Singh; J Suresh Chandra; B V Venkataraman
Journal:  Psychopharmacology (Berl)       Date:  2006-10-27       Impact factor: 4.530

4.  Estradiol and progesterone-induced slowing of gonadotropin-releasing hormone pulse frequency is not reversed by subsequent administration of mifepristone.

Authors:  Christopher R McCartney; Susan K Blank; John C Marshall
Journal:  Endocrine       Date:  2009-07-16       Impact factor: 3.633

5.  Mifepristone pretreatment reduces ethanol withdrawal severity in vivo.

Authors:  Lynda Sharrett-Field; Tracy R Butler; Jennifer N Berry; Anna R Reynolds; Mark A Prendergast
Journal:  Alcohol Clin Exp Res       Date:  2013-03-25       Impact factor: 3.455

6.  Estrous cycle phase and gonadal hormones influence conditioned fear extinction.

Authors:  M R Milad; S A Igoe; K Lebron-Milad; J E Novales
Journal:  Neuroscience       Date:  2009-09-15       Impact factor: 3.590

7.  Cancer- and endotoxin-induced cachexia require intact glucocorticoid signaling in skeletal muscle.

Authors:  Theodore P Braun; Aaron J Grossberg; Stephanie M Krasnow; Peter R Levasseur; Marek Szumowski; Xin Xia Zhu; Julia E Maxson; J Gabriel Knoll; Anthony P Barnes; Daniel L Marks
Journal:  FASEB J       Date:  2013-06-03       Impact factor: 5.191

8.  Central nervous system inflammation induces muscle atrophy via activation of the hypothalamic-pituitary-adrenal axis.

Authors:  Theodore P Braun; Xinxia Zhu; Marek Szumowski; Gregory D Scott; Aaron J Grossberg; Peter R Levasseur; Kathryn Graham; Sheehan Khan; Sambasivarao Damaraju; William F Colmers; Vickie E Baracos; Daniel L Marks
Journal:  J Exp Med       Date:  2011-11-14       Impact factor: 14.307

9.  A single-day treatment with mifepristone is sufficient to normalize chronic glucocorticoid induced suppression of hippocampal cell proliferation.

Authors:  Pu Hu; Charlotte Oomen; Anne-Marie van Dam; Jordi Wester; Jiang-Ning Zhou; Marian Joëls; Paul J Lucassen
Journal:  PLoS One       Date:  2012-09-25       Impact factor: 3.240

10.  Fluorescent ligand for human progesterone receptor imaging in live cells.

Authors:  Roy Weinstain; Joan Kanter; Beth Friedman; Lesley G Ellies; Michael E Baker; Roger Y Tsien
Journal:  Bioconjug Chem       Date:  2013-04-29       Impact factor: 4.774

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.